Oncogenic BRAF-V600E drives immune escape via prostaglandin E2/oncostatin M production in melanoma (P12)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 441891347

The project aims to uncover the mechanisms by which the BRAF-V600E mutation in malignant melanoma promotes immunosuppression within the tumor microenvironment, focusing specifically on the roles of Oncostatin M and prostaglandin E2 in modulating myeloid cells. To dissect this regulatory axis, we will employ in vitro co-culture systems as well as orthotopic and metastatic melanoma mouse models. As a translational approach, we will investigate the therapeutic potential of combining anti-OSMR antibodies with BRAF/MEK inhibitors and anti-PD-1 immunotherapy and validate our findings in human melanoma tissue samples.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1479: Oncogene-driven immune escape (OncoEscape)
• Applicant Institution: Albert-Ludwigs-Universität Freiburg
• Project Heads: Professor Dr. Justus Duyster; Dr. Julia Kolter, since 1/2026